Literature DB >> 17440731

A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder.

Hans-Helge Seifert1, Andrea Meyer, Marcus V Cronauer, Jiri Hatina, Mirko Müller, Harald Rieder, Michele J Hoffmann, Rolf Ackermann, Wolfgang A Schulz.   

Abstract

Several bladder cancer culture systems have been developed in recent years. However, reports about successful primary cultures of superficial urothelial carcinomas (UC) are sparse. Based on the specific growth requirements of UC described previously, we developed a new and reliable culture system for superficial low-grade UC. Between November 2002 and April 2006, 64 primary cultures of bladder cancer specimens were performed. After incubating the specimens overnight in 0.1% ethylenediaminetetraacetic acid solution, tumour cells could easily be separated from the submucosal tissue. Subsequently, cells were seeded in a low-calcium culture medium supplemented with 1% serum, growth factors, non-essential amino acids and glycine. The malignant origin of the cultured cells was demonstrated by spectral karyotyping. Overall culture success rate leading to a homogenous tumour cell population without fibroblast contamination was 63%. Culture success could be remarkably enhanced by the addition of glycine to the culture medium. Interestingly, 86.4% of pTa tumours were cultured successfully compared to only 50% of the pT1 and 38% of advanced stage tumours, respectively. G1 and G2 tumours grew significantly better than G3 tumours (86, 73 and 41%, respectively). Up to three passages of low-grade UC primary cultures were possible. We describe a new and reliable culture system, which is highly successful for primary culture and passage of low-grade UC of the bladder. Therefore, this culture system can widely be used for functional experiments on early stage bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440731     DOI: 10.1007/s00345-007-0166-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   3.661


  29 in total

1.  Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.

Authors:  Sarah V Williams; Jacqui Adams; Jane Coulter; Brenda M Summersgill; Janet Shipley; Margaret A Knowles
Journal:  Genes Chromosomes Cancer       Date:  2005-08       Impact factor: 5.006

2.  Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.

Authors:  J R Masters; P J Hepburn; L Walker; W J Highman; L K Trejdosiewicz; S Povey; M Parkar; B T Hill; P R Riddle; L M Franks
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

3.  Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

Authors:  Jorge Martínez-Torrecuadrada; Gabriela Cifuentes; Paula López-Serra; Pilar Saenz; Antonio Martínez; J Ignacio Casal
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

4.  Growth factors in bladder wound healing.

Authors:  L S Baskin; R S Sutherland; A A Thomson; H T Nguyen; D M Morgan; S W Hayward; Y K Hom; M DiSandro; G R Cunha
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

Review 5.  Experimental models of human bladder carcinogenesis.

Authors:  R A Crallan; N T Georgopoulos; J Southgate
Journal:  Carcinogenesis       Date:  2005-11-15       Impact factor: 4.944

6.  Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities.

Authors:  A Celis; H H Rasmussen; P Celis; B Basse; J B Lauridsen; G Ratz; B Hein; M Ostergaard; H Wolf; T Orntoft; J E Celis
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

7.  Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers.

Authors:  H Okuno; Y Kakehi; E Ozdemir; T Terachi; Y Okada; O Yoshida
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

8.  Influence of flow conditions and matrix coatings on growth and differentiation of three-dimensionally cultured rat hepatocytes.

Authors:  Henning C Fiegel; Joerg Havers; Ulrich Kneser; Molly K Smith; Tim Moeller; Dietrich Kluth; David J Mooney; Xavier Rogiers; Peter M Kaufmann
Journal:  Tissue Eng       Date:  2004 Jan-Feb

9.  Short-term culture of exfoliated cells from the urine of patients with bladder tumors.

Authors:  F Herz; D Deitch; S A Adler; D Brijlall
Journal:  Urol Res       Date:  1993-01

10.  Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients.

Authors:  J Harney; D M Murphy; M Jones; C Mothersill
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  11 in total

1.  Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.

Authors:  Annemarie Koch; Jiri Hatina; Harald Rieder; Hans-Helge Seifert; Wolfgang Huckenbeck; Frank Jankowiak; Andrea R Florl; Robert Stoehr; Wolfgang A Schulz
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

2.  Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer.

Authors:  Astrid Enkelmann; Joana Heinzelmann; Ferdinand von Eggeling; Martina Walter; Alexander Berndt; Heiko Wunderlich; Kerstin Junker
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-04       Impact factor: 4.553

Review 3.  [Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series].

Authors:  J Hatina; W Huckenbeck; H Rieder; H-H Seifert; W A Schulz
Journal:  Urologe A       Date:  2008-06       Impact factor: 0.639

4.  Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma.

Authors:  Annemarie Greife; Judith Knievel; Teodora Ribarska; Günter Niegisch; Wolfgang A Schulz
Journal:  Clin Epigenetics       Date:  2014-11-23       Impact factor: 6.551

5.  The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Authors:  Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real
Journal:  BMC Genomics       Date:  2015-05-22       Impact factor: 3.969

6.  Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.

Authors:  Judith Knievel; Wolfgang A Schulz; Annemarie Greife; Christiane Hader; Tobias Lübke; Ingo Schmitz; Peter Albers; Günter Niegisch
Journal:  Int J Mol Sci       Date:  2014-11-07       Impact factor: 5.923

7.  Tumor slice culture system to assess drug response of primary breast cancer.

Authors:  Kishan A T Naipal; Nicole S Verkaik; Humberto Sánchez; Carolien H M van Deurzen; Michael A den Bakker; Jan H J Hoeijmakers; Roland Kanaar; Maaike P G Vreeswijk; Agnes Jager; Dik C van Gent
Journal:  BMC Cancer       Date:  2016-02-09       Impact factor: 4.430

8.  APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression.

Authors:  Ananda Ayyappan Jaguva Vasudevan; Ulrike Kreimer; Wolfgang A Schulz; Aikaterini Krikoni; Gerald G Schumann; Dieter Häussinger; Carsten Münk; Wolfgang Goering
Journal:  Front Microbiol       Date:  2018-09-04       Impact factor: 5.640

9.  HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma.

Authors:  Ulrike Kreimer; Wolfgang A Schulz; Annemarie Koch; Günter Niegisch; Wolfgang Goering
Journal:  Front Oncol       Date:  2013-09-26       Impact factor: 6.244

10.  Canonical Notch signalling is inactive in urothelial carcinoma.

Authors:  Annemarie Greife; Silvia Jankowiak; Jochen Steinbring; Parvaneh Nikpour; Günter Niegisch; Michèle J Hoffmann; Wolfgang A Schulz
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.